Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).

Enrolling by invitation · Not applicable

Conditions studied: Lymph Node Dissection, Advanced Non-small Cell Lung Cancer (NSCLC)

In brief

Systemic mediastinal lymph node dissection is a standard step in radical surgery for advanced non-small cell lung cancer (NSCLC). However, it does not carry the risks associated with certain procedures (chylothorax, recurrent nerve palsy, diaphragmatic relaxation, intrapleural hemorrhage, injury to other chest organs (esophagus, great vessels), etc.). Data on their incidence and predictors in routine practice are limited. Objective: To assess trends and characteristics of projects directly related to Lymph Node Dissection and to identify independent risk factors for their development.

Key facts

Study ID: NCT07401498
Run by: Regional Clinical Oncology Dispensary
People needed: 1000
Starts: 2025-08-14
Expected to finish: 2026-08-01
Last updated by the study team: 2026-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥18 years.
Clinical stage IA-IIIB NSCLC (TNM 8th edition), oncologically radical resection is planned: anatomical segmentectomy/lobectomy/bilobectomy/pneumonectomy (including sleeve resection).
LND (systematic) is performed with mandatory inclusion of group 7 (subcarinal) lymph nodes.
Signed informed consent from all study patients.

You may not qualify if…

Small cell lung cancer, benign and metastatic tumors.
"Wedge" surgery without any lymph node dissection.
Nonemergency surgery; conversion is acceptable.
Patients who cannot complete 30 days of observation (no contact, etc.) should be excluded prior to surgery.

Where it is running

Regional Clinical Oncology Dispensary — Ulyanovsk, Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.